DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: S1 combined with cisplatin

First Posted Date: 2013-05-16

Last Posted Date: 2016-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 57

Registration Number: NCT01854749

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer

Phase 1

Conditions: Esophageal Cancer

Interventions: Radiation: Radiotherapy
Drug: Chemotherapy (5-FU+DDP)

First Posted Date: 2013-04-30

Last Posted Date: 2013-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT01843049

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Phase 2

Completed

Conditions: Non-small-cell Lung Cancer

Interventions: Drug: Gefitinib

First Posted Date: 2013-04-17

Last Posted Date: 2023-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 36

Registration Number: NCT01833572

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: S-1
Radiation: Radiation therapy

First Posted Date: 2013-04-15

Last Posted Date: 2019-02-15

Lead Sponsor: Fudan University

Target Recruit Count: 105

Registration Number: NCT01831531

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer

Conditions: Hypoxia
Breast Cancer

Interventions: Other: 18FMISO PET/CT scan
Drug: Letrozole

First Posted Date: 2013-03-20

Last Posted Date: 2013-03-20

Lead Sponsor: Fudan University

Target Recruit Count: 130

Registration Number: NCT01814449

Locations: 🇨🇳
Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: ABX Combined With Cisplatin
Drug: Gemcitabine Combined With Cisplatin

First Posted Date: 2013-03-13

Last Posted Date: 2016-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 84

Registration Number: NCT01810367

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Esophagectomy:Three-field Versus Two-field Lymphadenectomy (ECTOP-2002)

Not Applicable

Completed

Conditions: Esophageal Neoplasms

Interventions: Procedure: Lymphadenectomy

First Posted Date: 2013-03-08

Last Posted Date: 2023-07-20

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT01807936

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China

Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Phase 2

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: R-CHOP

First Posted Date: 2013-03-05

Last Posted Date: 2013-03-05

Lead Sponsor: Fudan University

Target Recruit Count: 196

Registration Number: NCT01804127

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

Interventions: Drug: gemcitabine

First Posted Date: 2013-02-25

Last Posted Date: 2016-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT01797913

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer

Phase 2

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Xeloda
Drug: QYHJ Granules

First Posted Date: 2013-02-22

Last Posted Date: 2013-02-22

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT01796782

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy